<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904146</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.7</org_study_id>
    <nct_id>NCT04904146</nct_id>
  </id_info>
  <brief_title>Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.</brief_title>
  <acronym>BIO-MUSE</acronym>
  <official_title>Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A translational study for identification of prognostic and treatment-predictive biomarkers in&#xD;
      Mycosis fungoides and Sézary syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2021</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">April 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of serum-protein markers.</measure>
    <time_frame>Blood samples are taken at baseline.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of serum-protein markers.</measure>
    <time_frame>Blood samples are taken at month 6.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of serum-protein markers.</measure>
    <time_frame>Blood samples are taken at month 12.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of serum-protein markers.</measure>
    <time_frame>Blood samples are taken at month 18.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of serum-protein markers.</measure>
    <time_frame>Blood samples are taken at month 24.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of serum-protein markers.</measure>
    <time_frame>Blood samples are taken at month 30.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of serum-protein markers.</measure>
    <time_frame>Blood samples are taken at month 36.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of immune cell profile-protein markers.</measure>
    <time_frame>Blood samples are taken at baseline.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of immune cell profile-protein markers.</measure>
    <time_frame>Blood samples are taken at month 6.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of immune cell profile-protein markers.</measure>
    <time_frame>Blood samples are taken at month 12.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of immune cell profile-protein markers.</measure>
    <time_frame>Blood samples are taken at month 18.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of immune cell profile-protein markers.</measure>
    <time_frame>Blood samples are taken at month 24.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of immune cell profile-protein markers.</measure>
    <time_frame>Blood samples are taken at month 30.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of immune cell profile-protein markers.</measure>
    <time_frame>Blood samples are taken at month 36.</time_frame>
    <description>Analysis of blood samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of the lymphoma microenvironment in skin.</measure>
    <time_frame>Blood samples are taken at baseline.</time_frame>
    <description>Analysis of lymphocyte subsets in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the lymphoma microenvironment in skin.</measure>
    <time_frame>Blood samples are taken at month 6.</time_frame>
    <description>Analysis of lymphocyte subsets in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the lymphoma microenvironment in skin.</measure>
    <time_frame>Blood samples are taken at month 12.</time_frame>
    <description>Analysis of lymphocyte subsets in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the lymphoma microenvironment in skin.</measure>
    <time_frame>Blood samples are taken at month 18.</time_frame>
    <description>Analysis of lymphocyte subsets in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the lymphoma microenvironment in skin.</measure>
    <time_frame>Blood samples are taken at month 24.</time_frame>
    <description>Analysis of lymphocyte subsets in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the lymphoma microenvironment in skin.</measure>
    <time_frame>Blood samples are taken at month 30.</time_frame>
    <description>Analysis of lymphocyte subsets in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the lymphoma microenvironment in skin.</measure>
    <time_frame>Blood samples are taken at month 36.</time_frame>
    <description>Analysis of lymphocyte subsets in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin barrier and skin microbiology profile.</measure>
    <time_frame>Is performed at baseline.</time_frame>
    <description>Skin barrier analyzed by transepidermal water loss of the skin on both healthy and affected skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin barrier and skin microbiology profile.</measure>
    <time_frame>Is performed at month 6.</time_frame>
    <description>Skin barrier analyzed by transepidermal water loss of the skin on both healthy and affected skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin barrier and skin microbiology profile.</measure>
    <time_frame>Is performed at month12.</time_frame>
    <description>Skin barrier analyzed by transepidermal water loss of the skin on both healthy and affected skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin barrier and skin microbiology profile.</measure>
    <time_frame>Is performed at month18.</time_frame>
    <description>Skin barrier analyzed by transepidermal water loss of the skin on both healthy and affected skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin barrier and skin microbiology profile.</measure>
    <time_frame>Is performed at month 24.</time_frame>
    <description>Skin barrier analyzed by transepidermal water loss of the skin on both healthy and affected skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin barrier and skin microbiology profile.</measure>
    <time_frame>Is performed at month 30.</time_frame>
    <description>Skin barrier analyzed by transepidermal water loss of the skin on both healthy and affected skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin barrier and skin microbiology profile.</measure>
    <time_frame>Is performed at month 36.</time_frame>
    <description>Skin barrier analyzed by transepidermal water loss of the skin on both healthy and affected skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at baseline.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 3.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 6.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 9.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 12.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 15.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 18.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 21.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 24.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 27.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 30.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 33.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes in lymphoma T cells and host T cells.</measure>
    <time_frame>Blood samples are taken at month 36.</time_frame>
    <description>Analysis of fresh blood.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mycosis Fungoides</condition>
  <condition>Sezary Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients with Mycosis fungoides and Sézary syndrome</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volontaires</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.</intervention_name>
    <description>The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.</description>
    <arm_group_label>Healthy volontaires</arm_group_label>
    <arm_group_label>Patients with Mycosis fungoides and Sézary syndrome</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      • Lymphocyte subpopulations:&#xD;
&#xD;
        -  Basic examination lymphocytes: CD3, CD4, CD8, CD19, CD16/56&#xD;
&#xD;
        -  T regs: CD4, CD25, CD194, CD127, CD45RO, HLA-DR&#xD;
&#xD;
        -  Naive and memory T-cells including TH1, TH2, TH17: CD4, CD8, CD197, CD45RA, CD183, CD196&#xD;
&#xD;
        -  Follicular helper T cells: CD4, CD185&#xD;
&#xD;
        -  T-cells : CD4, CD8, CD197, CD45RA, CD38, HLA-DR&#xD;
&#xD;
        -  Other leukocytes, at the discretion of the treating physician&#xD;
&#xD;
        -  sILR2R, IL6, IL1 beta, IL-8, IL10, TARC&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mycosis fungoides and Sézary syndrome (n=120) are recruited in the study.&#xD;
&#xD;
        As a control group, healthy volonteers (n=20) are recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-100 years&#xD;
&#xD;
          -  Histologically confirmed (according to the World Health Organization (WHO)/EORTC&#xD;
             classification) MF/SS stages I-IV&#xD;
&#xD;
          -  WHO performance status 0 -3&#xD;
&#xD;
          -  Absence of psychiatric illness or condition which could interfere with the subjects'&#xD;
             ability to understand the requirements of the study.&#xD;
&#xD;
          -  Written informed consent according to International Conference on Harmonization&#xD;
             (ICH)/(Good Clinical Practice (GCP), and Swedish regulations&#xD;
&#xD;
          -  No minimum or maximum required routine laboratory data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Not applicable. No exclusion criteria are specified.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Drott, MD, PhD</last_name>
      <phone>+46 46 17 75 20</phone>
      <email>kristina.drott@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Jan Sundberg, RN</last_name>
      <phone>+46 46 17 70 34</phone>
      <email>jan.sundberg@skane.se</email>
    </contact_backup>
    <investigator>
      <last_name>Kristina Drott, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin lymphoma</keyword>
  <keyword>Mycosis fungoides</keyword>
  <keyword>Sezary syndrome</keyword>
  <keyword>Translational research</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Treatment prediction</keyword>
  <keyword>Lymphoma microenvironment</keyword>
  <keyword>Skin neoplasms</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

